Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Dr Reddy’s Laboratories ( (RDY) ) has provided an update.
Dr. Reddy’s Laboratories announced that ICRA Limited has reaffirmed its credit rating for the company’s bank facilities at [ICRA]AA+ (Stable). This rating applies to the company’s fund-based and non-fund-based limits, reflecting a stable outlook and strong creditworthiness. The reaffirmation of this credit rating indicates confidence in Dr. Reddy’s financial health and operational stability, which can positively impact the company’s reputation and reliability among investors and stakeholders.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd. is a prominent pharmaceutical company headquartered in Hyderabad, India. It is primarily engaged in the manufacturing and marketing of generic medicines, active pharmaceutical ingredients, and proprietary products. The company operates within the global healthcare industry, focusing on providing affordable and innovative medicine to patients worldwide.
YTD Price Performance: 12.42%
Average Trading Volume: 1,100,045
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $13.26B
See more insights into RDY stock on TipRanks’ Stock Analysis page.
